Llwytho...
Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with impro...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Manag Res |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513839/ https://ncbi.nlm.nih.gov/pubmed/28744160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S139305 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|